Investigations by Japanese universities found data had been manipulated in studies on Diovan, a blood-pressure drug manufactured by Swiss drug maker Novartis. The WSJ's Kana Inagaki tells Mariko ...

Problems surrounding the blood pressure-lowering drug Diovan have shed fresh light on opaque and sometimes questionable ties between medical researchers and pharmaceutical firms. More facts behind ...

Valsartan and Hydrochlorothiazide Tablets USP, 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg, had U.S. sales of approximately$1.6 billion for the 12 months ending June 30, 2012 ...

BASEL -- Swiss drug-maker Novartis AG Wednesday said its best-selling drug, the high-blood-pressure treatment Diovan, was well on track to soon achieve annual sales of $4 billion. At a ...

It now expects the long-delayed U.S. release of a generic of its blockbuster Diovan to happen in the second quarter and by summer's end hopes to have completed the strategic review that will ...

Novartis' ($NVS) blockbuster Diovan has enjoyed nearly 18 months of sales unscathed by generics since its patent expired in September 2012, but the after-party may be ...

The FDA has approved Novartis’ Diovan HCT (valsartan/hydrochlorothiazide tablets) and Exforge (amlodipine/valsartan tablets) as first-line therapies for hypertension in patients likely to need ...

The Food and Drug Administration (FDA) has expanded the approval of Diovan (valsartan) to include patients 1 to 5 years of age for the treatment of hypertension. Previously, the treatment was ...

This leaflet answers some common questions about Co-Diovan. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. The information ...